A management-led syndicate of prominent investors acquired a majority stake in Histosonics Inc. that values the company at ...

With half-year industry financings down 59% from last year, and a U.S. administration supportive of cryptocurrencies, ...

The difference between the origin of Alzheimer's disease (AD) and its symptoms is an obstacle to finding effective treatments ...

Quantumpharm Inc., known as Xtalpi Inc., announced receiving $51 million up front from a potential $5.99 billion deal with ...

Neucore Bio Inc. announced it has been awarded a US$304,000 National Science Foundation Small Business Technology Transfer grant to evaluate scalable manufacturing of exosome-based gene delivery ...

Starlight Therapeutics Inc., a wholly owned subsidiary of Lantern Pharma Inc., announced that the FDA has cleared STAR-001 (LP-184) in combination with spironolactone for patients with glioblastoma ...

DNA vaccines are a promising therapeutic approach for personalized cancer immunotherapy. However, the application of therapeutic DNA-based cancer vaccines is still limited by their variable clinical ...

Rivo Bio Inc. has disclosed compounds acting as 5-HT2A receptor agonists reported to be useful for the treatment of depression, schizophrenia and anxiety disorders.

Glioblastoma multiforme (GBM) is an aggressive brain tumor characterized by cellular heterogeneity, therapy-resistant glioblastoma stem cells (GSCs), and diffuse infiltration. Researchers at City of ...

Pharmaceutical Technology Co. Ltd., Quanzhou Haichuang Pharmaceutical Technology Co. Ltd. and Suzhou Grandkol Pharm Technology Co. Ltd. have discovered new compounds.

Hefei Institutes of Physical Science Chinese Academy of Sciences has synthesized phosphoglycerate kinase 1 (PGK1) inhibitors reported to be useful for the treatment of inflammatory bowel disease.

Nitrogen-containing heteroaromatic-based inhibitors for cytochrome P450 (CYP) in various species contain a crucial coordination between the nitrogen atom and the heme iron. Previous studies suggested ...